| 摘要 |
Disclosed is a compound of formula (I) wherein: At least one of the positions 6 or 7 of the quinazoline ring must be substituted by a group A and the remaining positions are optionally substituted by up to three R2 groups; X is N, CH or a C-CN group; R1 is independently aryl or heteroaryl substituted by at least one R6 group and optionally substituted by up to three R5 groups where R5 and R6 are as described in the specification; R2 represents H, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, optionally substituted as defined; and A is represented by formula (II) wherein: T represents alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl optionally substituted as defined; L is N or a CR4 group where R4 is as defined in the specification; Q is selected from CR3R11R12 or NR11R12 where R3 is the same as R2 above and R11 and R12 are as defined; D represents H, trifluoromethyl, difluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -SO2NR9R7, -C(O)R9, -OC(O)R9 or -C(O)NR7R9 optionally substituted as defined; and The remaining substituents are as defined in the specification. Compounds of the type discloser are EGFR and ErbB2 inhibitors useful in the treatment of hyperproliferative diseases.
|
